2-(4-Methoxyphenyl)-2-adamantanemethanamine hydrochloride | 287173-18-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(4-Methoxyphenyl)-2-adamantanemethanamine hydrochloride
• 英文别名: [2-(4-Methoxyphenyl)-2-adamantyl]methanamine;hydrochloride
• CAS: 287173-18-6
• 化学式: C₁₈H₂₅NO*ClH
• 分子量: 307.864
• InChiKey: RLTJRXWLRNCLRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.77
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  35.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-(4-methoxyphenyl)adamantan-2-ol 生成 2-(4-Methoxyphenyl)-2-adamantanemethanamine hydrochloride
  参考文献：
  名称：

  2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission

  摘要：

  在说明书中披露的公式（1）化合物的使用，其中R1、R2、R3、R4、R5和R6可独立选择为氢、烷基和芳基，或其药用盐，但其中R1至R4和R6为氢时，R5不可选择自CH2CH2NHSO2CH3、CH2CH2NHSO2CF3和甲基被SO2NH2、SO3H、PO3H2、CONHOH或从公式（a）、（b）、（c）、（d）和（e）中选择的杂环基团，用于制造用于治疗通常与谷氨酸能传递异常相关的病况的药物。

  公开号：

  US06531511B1

文献信息

• 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION
  申请人：VERNALIS RESEARCH LIMITED

  公开号：EP1143964A1

  公开（公告）日：2001-10-17
• US6531511B1
  申请人：——

  公开号：US6531511B1

  公开（公告）日：2003-03-11
• [EN] 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION<br/>[FR] COMPOSES DE 2-ADAMANTANEMETHANAMINE DESTINES AU TRAITEMENT D'ANOMALIES DE LA TRANSMISSION GLUTAMATERGIQUE
  申请人：VERNALIS RESEARCH LIMITED

  公开号：WO2000044371A1

  公开（公告）日：2000-08-03

  The use of a compound of formula (1), wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl and aryl, or pharmaceutically acceptable salts thereof, with the proviso that wherein R1 to R4 and R6 are hydrogen, R5 is not selected from CH2CH2NHSO2CH3, CH2CH2NHSO2CF3 and methyl substituted by SO2NH2, SO3H, PO3H2, CONHOH or a heterocyclic group selected from formulae (a), (b), (c), (d) and (e) in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission.
• 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
  申请人：Vernalis Research Limited

  公开号：US06531511B1

  公开（公告）日：2003-03-11

  The use of a compound of formula (1), as disclosed in the specification, wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl and aryl, or pharmaceutically acceptable salts thereof, with the proviso that wherein R1 to R4 and R6 are hydrogen, R5 is not selected from CH2CH2NHSO2CH3, CH2CH2NHSO2CF3 and methyl substituted by SO2NH2, SO3H, PO3H2, CONHOH or a heterocyclic group selected from formulae (a), (b), (c), (d) and (e) in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission.

  在说明书中披露的公式（1）化合物的使用，其中R1、R2、R3、R4、R5和R6可独立选择为氢、烷基和芳基，或其药用盐，但其中R1至R4和R6为氢时，R5不可选择自CH2CH2NHSO2CH3、CH2CH2NHSO2CF3和甲基被SO2NH2、SO3H、PO3H2、CONHOH或从公式（a）、（b）、（c）、（d）和（e）中选择的杂环基团，用于制造用于治疗通常与谷氨酸能传递异常相关的病况的药物。